Enlivex Therapeutics Ltd (ENLV) - News Archive

Abstract: Enlivex Therapeutics Ltd. has reported compelling interim results from its Phase I clinical trial of Allocetra, an innovative macrophage reprogramming immunotherapy. This article examines the data from the stu...

In a recent announcement, Enlivex Therapeutics Ltd. shared its plans to host an investor webinar aimed at discussing the promising interim data from its Phase I/II Allocetra trial, specifically for patients suffering fr...

On December 5, 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a pioneering company specializing in macrophage reprogramming immunotherapy, unveiled positive interim efficacy data from the Phase I stage of its Allocetra...

In a strategic move reflecting a growing trend among forward-thinking corporations, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focusing on innovative macrophage reprogramming immunotherapies, has...

Recently, Enlivex Therapeutics Ltd. made a significant announcement regarding its ongoing clinical trial of Allocetra, aimed at patients suffering from moderate to severe knee osteoarthritis. This critical development f...

Enlivex Achieves Regulatory Milestone with Phase I Trial Authorization for Allocetra™ in Psoriatic Arthritis PatientsEnlivex Therapeutics Ltd, a clinical-stage immunotherapy company, has received regulatory authorizatio...

Enlivex Therapeutics Ltd. is making significant strides in the field of macrophage reprogramming immunotherapy with its innovative drug candidate, Allocetra™. The company has recently announced the dosing of the first t...

Nes-Ziona, Israel May 29, 2024 Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company specializing in macrophage reprogramming, has recently closed a registered direct offering to a single heal...

Enlivex Therapeutics Secures $15 Million in Registered Direct Offering, Boosting Shareholder ConfidenceEnlivex Therapeutics Ltd., a leading immunotherapy company specializing in macrophage reprogramming, has recently an...

Nes-Ziona, Israel, April 22, 2024 - Enlivex Therapeutics Ltd., a revolutionary force in macrophage reprogramming immunotherapy, takes a significant step forward in the battle against knee osteoarthritis. The clinical-st...

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced that the Danish Medicines Agency (DKMA) has authorized the expansion of a multi-country clinical trial evaluating...

Your TitleDatePromising Results Revealed in Enlivex s Phase II Trial of Allocetra in Sepsis PatientsNes-Ziona, Israel Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a leading clinical-stage macrophage reprogramming immunothe...

Enlivex Receives IMOH Regulatory Authorization for a Phase I/II Trial Evaluating Allocetra in Knee Osteoarthritis PatientsEnlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has r...